inclusion criteria: subjects must meet all of the following criteria for inclusion: 1. 18-60 years of age 2. positive for presence of sars-cov-2 on np or op swab by fda-authorized rt-pcr test within seven days prior to infusion 3. at least one current symptom of covid-19, onset within seven days prior to infusion: * fever or chills * cough * shortness of breath or difficulty breathing * fatigue * muscle or body aches * headache * new loss of taste or smell * sore throat * congestion or runny nose * nausea or vomiting * diarrhea 4. able to understand the study and comply with all study procedures 5. agrees not to participate in any other trial of an investigational product during the study period 6. willing and able to provide written informed consent prior to the start of any study related activities 7. if female, meets at least one of the following reproductive risk criteria * post-menopausal for at least 12 months * use of one or more of the following highly effective contraceptive methods for at least 90 days following the last dose of study product: combined estrogen and progestogen containing or progestogen-only hormonal contraception, intrauterine device (iud), intrauterine hormone-releasing system, surgical bilateral tubal occlusion * vasectomized sole sexual partner who has received medical assessment of the surgical success 8. male and female subjects agree to sexual abstinence (refraining from heterosexual intercourse for at least 90 days following the last dose of study product) if not using birth control or condoms for males.

inclusion criteria: subjects must meet all of the following criteria for inclusion: 1. 18-60 years of age 2. positive for presence of sars-cov-2 on np or op swab by fda-authorized rt-pcr test within seven days prior to infusion 3. at least one current symptom of covid-19, onset within seven days prior to infusion: * fever or chills * cough * shortness of breath or difficulty breathing * fatigue * muscle or body aches * headache * new loss of taste or smell * sore throat * congestion or runny nose * nausea or vomiting * diarrhea 4. able to understand the study and comply with all study procedures 5. agrees not to participate in any other trial of an investigational product during the study period 6. willing and able to provide written informed consent prior to the start of any study related activities 7. if female, meets at least one of the following reproductive risk criteria * post-menopausal for at least 12 months * use of one or more of the following highly effective contraceptive methods for at least 90 days following the last dose of study product: combined estrogen and progestogen containing or progestogen-only hormonal contraception, intrauterine device (iud), intrauterine hormone-releasing system, surgical bilateral tubal occlusion * vasectomized sole sexual partner who has received medical assessment of the surgical success 8. male and female subjects agree to sexual abstinence (refraining from heterosexual intercourse for at least 90 days following the last dose of study product) if not using birth control or condoms for males.

inclusion criteria: subjects must meet all of the following criteria for inclusion: 18-60 years of age positive for presence of sars-cov-2 on np or op swab by fda-authorized rt-pcr test within seven days prior to infusion at least one current symptom of covid-19, onset within seven days prior to infusion: fever or chills cough shortness of breath or difficulty breathing fatigue muscle or body aches headache new loss of taste or smell sore throat congestion or runny nose nausea or vomiting diarrhea able to understand the study and comply with all study procedures agrees not to participate in any other trial of an investigational product during the study period willing and able to provide written informed consent prior to the start of any study related activities if female, meets at least one of the following reproductive risk criteria post-menopausal for at least 12 months use of one or more of the following highly effective contraceptive methods for at least 90 days following the last dose of study product: combined estrogen and progestogen containing or progestogen-only hormonal contraception, intrauterine device (iud), intrauterine hormone-releasing system, surgical bilateral tubal occlusion vasectomized sole sexual partner who has received medical assessment of the surgical success male and female subjects agree to sexual abstinence (refraining from heterosexual intercourse for at least 90 days following the last dose of study product) if not using birth control or condoms for males.

inclusion criteria: subjects must meet all of the following criteria for inclusion: 18-60 years of age positive for presence of sars-cov-2 on np or op swab by fda-authorized rt-pcr test within seven days prior to infusion at least one current symptom of covid-19, onset within seven days prior to infusion: fever or chills cough shortness of breath or difficulty breathing fatigue muscle or body aches headache new loss of taste or smell sore throat congestion or runny nose nausea or vomiting diarrhea able to understand the study and comply with all study procedures agrees not to participate in any other trial of an investigational product during the study period willing and able to provide written informed consent prior to the start of any study related activities if female, meets at least one of the following reproductive risk criteria post-menopausal for at least 12 months use of one or more of the following highly effective contraceptive methods for at least 90 days following the last dose of study product: combined estrogen and progestogen containing or progestogen-only hormonal contraception, intrauterine device (iud), intrauterine hormone-releasing system, surgical bilateral tubal occlusion vasectomized sole sexual partner who has received medical assessment of the surgical success male and female subjects agree to sexual abstinence (refraining from heterosexual intercourse for at least 90 days following the last dose of study product) if not using birth control or condoms for males.

inclusion criteria: subjects must meet all of the following criteria for inclusion: 1. 18-60 years of age 2. positive for presence of sars-cov-2 on np or op swab by fda-authorized rt-pcr test within seven days prior to infusion 3. at least one current symptom of covid-19, onset within seven days prior to infusion: - fever or chills - cough - shortness of breath or difficulty breathing - fatigue - muscle or body aches - headache - new loss of taste or smell - sore throat - congestion or runny nose - nausea or vomiting - diarrhea 4. able to understand the study and comply with all study procedures 5. agrees not to participate in any other trial of an investigational product during the study period 6. willing and able to provide written informed consent prior to the start of any study related activities 7. if female, meets at least one of the following reproductive risk criteria - post-menopausal for at least 12 months - use of one or more of the following highly effective contraceptive methods for at least 90 days following the last dose of study product: combined estrogen and progestogen containing or progestogen-only hormonal contraception, intrauterine device (iud), intrauterine hormone-releasing system, surgical bilateral tubal occlusion - vasectomized sole sexual partner who has received medical assessment of the surgical success 8. male and female subjects agree to sexual abstinence (refraining from heterosexual intercourse for at least 90 days following the last dose of study product) if not using birth control or condoms for males.

inclusion criteria: subjects must meet all of the following criteria for inclusion: 1. 18-60 years of age 2. positive for presence of sars-cov-2 on np or op swab by fda-authorized rt-pcr test within seven days prior to infusion 3. at least one current symptom of covid-19, onset within seven days prior to infusion: - fever or chills - cough - shortness of breath or difficulty breathing - fatigue - muscle or body aches - headache - new loss of taste or smell - sore throat - congestion or runny nose - nausea or vomiting - diarrhea 4. able to understand the study and comply with all study procedures 5. agrees not to participate in any other trial of an investigational product during the study period 6. willing and able to provide written informed consent prior to the start of any study related activities 7. if female, meets at least one of the following reproductive risk criteria - post-menopausal for at least 12 months - use of one or more of the following highly effective contraceptive methods for at least 90 days following the last dose of study product: combined estrogen and progestogen containing or progestogen-only hormonal contraception, intrauterine device (iud), intrauterine hormone-releasing system, surgical bilateral tubal occlusion - vasectomized sole sexual partner who has received medical assessment of the surgical success 8. male and female subjects agree to sexual abstinence (refraining from heterosexual intercourse for at least 90 days following the last dose of study product) if not using birth control or condoms for males.